KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Debt (2017 - 2020)

Xenon Pharmaceuticals (XENE) has disclosed Total Debt for 4 consecutive years, with $15.7 million as the latest value for Q1 2020.

  • Quarterly Total Debt rose 3.55% to $15.7 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $15.7 million through Mar 2020, up 3.55% year-over-year, with the annual reading at $15.5 million for FY2019, N/A changed from the prior year.
  • Total Debt for Q1 2020 was $15.7 million at Xenon Pharmaceuticals, up from $15.5 million in the prior quarter.
  • The five-year high for Total Debt was $15.7 million in Q1 2020, with the low at $6.8 million in Q4 2017.
  • Average Total Debt over 4 years is $13.0 million, with a median of $15.1 million recorded in 2019.
  • Peak annual rise in Total Debt hit 120.17% in 2019, while the deepest fall reached 3.47% in 2019.
  • Over 4 years, Total Debt stood at $6.8 million in 2017, then surged by 118.78% to $14.9 million in 2018, then rose by 4.39% to $15.5 million in 2019, then grew by 0.88% to $15.7 million in 2020.
  • According to Business Quant data, Total Debt over the past three periods came in at $15.7 million, $15.5 million, and $15.4 million for Q1 2020, Q4 2019, and Q3 2019 respectively.